Abstract
Progesterone antagonist RU486 (mifepristone) has been implicated for many anti-neoplastic and obstetrical applications. But the compound has demonstrated undesired agonist-like effect depending on cell, tissue and species studied. Using PR-transfected breast cancer cells MDA-MB-231, this report describes the similarities and differences between progesterone- and RU486-mediated effects on cell growth, cell differentiation and, at the molecular level, on the activation of p44/p42 MAP kinases (MAPK). Like progesterone, RU486 inhibited cells growth by arresting the cells in G0/G1 phase of the cell cycle. In contrast to progesterone that induced cell spreading, RU486 induced a multipolar, stellate morphology. RU486-treated cells showed no increase of stress fibers, nor was there any increase of focal adhesions as progesterone-treated cells did. Furthermore, despite of the fact that both compounds inhibited cell growth, RU486 significantly stimulated the activation of p44/p42 MAP kinases whereas progesterone markedly inhibited the activation. Nonetheless, the effects of RU486 were PR-mediated and RU486 was able to antagonize the effect of progesterone on cell growth and focal adhesion. In conclusion, RU486 can act not only as a progesterone antagonist, a progesterone agonist but also induced morphological and molecular changes that were distinct from progesterone-mediated effects in PR-transfected MDA-MB-231 cells. The non-progesterone-like effect of RU486 may be mediated through a pathway that is different from the progesterone-mediated pathway, or it is the result of a blockade of certain critical step(s) in the progesterone-mediated pathway. In any case, undesired side effects of antiprogestin may create clinical complications. PR-transfected MDA-MB-231 breast cancer cells provide a model for studying the functions of progesterone analogues. © 2001 Cancer Research Campaign http://www.bjcancer.com
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Beck CA, Zhang YX, Weigel NL and Edwards DP (1996) Two types of antiprogestins have distinct effects on site-specific phosphorylation of human progesterone receptor. J Biol Chem 271: 1209–1217
Bocquel M-T, Ji J, Ylikomc T, Benhamou B, Vergezac A, Chambon P and Gronemeyer H (1993) Type II antagonists impair the DNA binding of steroid hormone receptors without affecting dimerization. J Steroid Biochem Mol Biol 45: 205–215
Cadepond F, Ulman A and Baulieu E-E (1997) RU486 (Mifepristone): Mechanisms of action and clinical uses. Annu Rev Med 48: 129–156
Conneely OM, Mulac-Jericevic B, Lydon JP and De Mayo FJ (2001) Reproductive functions of the progesterone receptor lessens from knock-out mice. Mol Cell Endocrinol 179: 97–103
Dent P, Jarvis WD, Birrer MJ, Fisher PB, Schmidt-Ullrich RK and Grant S (1998) The roles of signaling by the p42/p44 mitogen-activated protein (MAP) kinase pathway; a potential route to radio-and chemo-sensitization of tumor cells resulting in the induction of apoptosis and loss of clonogenicity. Leukemia 12: 1843–1850
El-Ashry D, Onate SA, Nordeen SK and Edwards DP (1989) Human progesterone receptor complexed with the antagonist RU 486 binds to hormone response elements in a structurally altered form. Mol Endocrinol 3: 1545–1558
Fuhrmann U, Hess-Stumpp H, Cleve A, Neef G, Schwede W, Hoffmann J, Fritzemeier KH and Chwalisz K (2000) Synthesis and biological activity of a novel, highly potent progesterone receptor antagonist. J Med Chem 43: 5010–5016
Gaillard RC and Herrmann W (1983) Clinical use of RU 486: control of the menstrual cycle and effect on the hypophyseal-adrenal axis. Ann Endocrinol (Paris) 44: 345–346
Gravanis A and Schaison George M et al (1985) Endometrial and pituitary responses to the steroidal antiprogestin RU486 in postmenopausal women. J Clin Endocr Metab 60: 156–163
Guiochon-Mantel A, Loosfelt H, Ragot T, Bailly A, Atger M, Misrahi M, Perricaudet M and Milgrom E (1988) Receptors bound to antiprogestin from abortive complexes with hormone responsive elements. Nature 336: 695–698
Hall A (1998) Rho GTPases and the actin cytoskeleton. Science 279: 509–514
Herrmann W, Wyss R, Riondel A, Philibert D, Teutsch G, Sakiz E and Baulieu EE (1982) The effects of an antiprogesterone steroid in women: interruption of the menstrual cycle and of early pregnancy. C R Seances Acad Sci III 294: 933–938
Horwitz KB, Tung L and Takimoto GS (1995) Novel mechanisms of antiprogestin action. J Steroid Biochem Molec Biol 53: 9–17
Jackson TA, Richer JK, Bain DL, Takimoto GS and Horwitz KB (1997) The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/Spa and the corepressors N-CoR or SMRT. Mol Endocrinol 11: 693–705
Kastner P, Bocquel M-T, Turcotte B, Garnier J-M, Horwitz KB, Chambon P and Gronemeyer H (1990) Transient expression of human and chicken progesterone receptors does not support alternative translational initiation from a single mRNA as the mechanism generating two receptor isoforms. J Biol Chem 265: 12163–12167
Klein-Hitpass L, Cato ACB, Henderson D and Ryffel G (1991) Two types of antiprogestins identified by their differential action in transcriptionally active extracts from T47D cells. Nucl Acid Res 19: 1227–1234
Lin VC-L, Ng E-H, Aw S-E, Tan MG-K, Ng EH-L, Chan VS-W and Ho GH (1999) Progestins inhibit the growth of MDA-MB-231 cells transfected with progesterone receptor complementary DNA. Clin Cancer Res 5: 395–404
Lin VCL, Ng EH, Aw SE, Tan MG-K, Ng EH-L and Bay BH (2000) Progesterone induces cell spreading and focal adhesion in breast cancer cells MDA-MB-231 transfected with progesterone receptor cDNA. Mol Endocrinol 14: 348–358
Meyer ME, Pmon A, Bocquel M-T, Chambon P and Gronemeyer H (1990) Agonistic and antagonist activities of RU486 on the function of the human progesterone receptor. EMBO J 9: 3923–3932
Nordeen SK, Bona BJ and Moyer ML (1993) Latent agonist activity of the steroid antagonist, RU486, is unmasked in cells treated with activators of protein kinase A. Mol Endocrinol 7: 731–742
Rocereto TF, Saul HM, Aikins JA Jr and Paulson J (2000) Phase II study of Mifepristone (RU486) in refactory ovarian cancer. Gynecol Oncol 77: 429–432
Sartorius CA, Groshong SD, Miller LA, Powell RL, Tung L, Takimoto GS and Horwitz KB (1994) New T47D breast cancer cell lines for the independent study of progesterone B-and A-receptors: only antiprogestin-occupied B-receptors are switched to transcriptional agonists by cAMP. Cancer Res 54: 3868–3877
Sebolt-Leopold JS (2000) Development of anticancer drugs targeting the MAP kinase pathway. Oncogene 19: 6594–6599
Simth CL, Nawaz Z and O’Malley BW (1997) Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. Mol Endocrinol 11: 657–666
Spitz IM and Chwalisz K (2000) Progesterone receptor modulators and progesterone antagonists in women’s health. Steroids 65: 807–815
Takimoto GS, Graham JD, Jackson TA, Tung L, Powell RL, Horwitz LD and Horwitz KB (1999) Tamoxifen resistant breast cancer: coregulators determine the direction of transcription by antagonist-occupied steroid receptors. J Steroid Biochem Mol Biol 69: 45–50
Truss M, Bartsch J and Beato M (1994) Antiprogestins prevent progesterone receptor binding to hormone response elements in vivo. Proc Natl Acad Sci USA 91: 11333–11337
Tung L, Mohamed KM, Hoeffler JP, Takimoto GS and Horwitz KB (1993) Antagonist occupied human progesterone B-receptors activate transcription without binding to progesterone response elements, and are dominantly inhibited by A-receptors. Mol Endocrinol 7: 1256–1265
Vindelov LL, Christensen IJ and Nissen NI (1983) A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry 3: 323–327
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Lin, VL., Aw, S., Ng, E. et al. Demonstration of mixed properties of RU486 in progesterone receptor (PR)-transfected MDA-MB-231 cells: a model for studying the functions of progesterone analogues. Br J Cancer 85, 1978–1986 (2001). https://doi.org/10.1054/bjoc.2001.2167
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2001.2167
Keywords
This article is cited by
-
Antiprogestin mifepristone inhibits the growth of cancer cells of reproductive and non-reproductive origin regardless of progesterone receptor expression
BMC Cancer (2011)
-
In vitro evaluation of the growth inhibition and apoptosis effect of mifepristone (RU486) in human Ishikawa and HEC1A endometrial cancer cell lines
Cancer Chemotherapy and Pharmacology (2008)